On the stock market since 1986, it operates in the world of health and science. It has 181 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
The gap is $9.4M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 17% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, executives reported 12 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, PDEX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: PDEX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.